Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of NO synthase (NOS), has also been associated with impaired endothelial function and with uterine artery flow disturbances that are characteristic for preeclampsia [24,26,27]. This evidence concerns the gene NOS1 and preeclampsia.